



2023–2024

# PCRS ANNUAL REPORT



PACIFIC COAST  
REPRODUCTIVE  
SOCIETY

# OUTGOING PRESIDENT'S MESSAGE

Dear PCRS Members & Supporters,

It has been an honor to serve as the President, especially as the second nurse practitioner in PCRS history to hold this role. Throughout my tenure, I have focused on fostering engagement, implementing our strategic initiatives, and strengthening the structure of PCRS to ensure its continued growth and success.

One of my proudest accomplishments was the enrichment of the Abstract/Awards, Scholarship, Grant, Membership, Program, Social Media/Communications Committees. Each committee is now led by a PCRS Board of Directors, which has enhanced our organizational structure. I established written charters for each committee, outlining their purpose, goals, and action items directly aligned with the 2023 Strategic Planning Meeting.

Since the launch of these committees at the March PCRS Annual Meeting, we have experienced a notable increase in member engagement. Many members have volunteered to join these committees, allowing us to broaden our scope and impact. For example, the Social Media Committee launched PCRS profiles on Instagram, LinkedIn, and Facebook and the Membership Committee is developing a member survey to better understand and meet the needs of the PCRS community.

I am excited to share that the 2024 Annual Meeting was a success, becoming the largest event in PCRS history with 522 conference attendees and 400 vendor participants. This milestone would not have been possible without the efforts of the Program Committee, who developed excellent topics and speakers and our industry partners, who showcased their latest innovations and contributed greatly to our ability to network and learn.

I would also like to extend my gratitude to the incredible team at SBI Association Management. Their behind-the-scenes efforts are instrumental to the success of our society. SBI developed a first ever Board Orientation which has been valuable to outline PCRS history, Governance, Vision, Values, fiduciary duties of directors, and board member responsibilities.

The financial status of PCRS has remained robust, and our investment accounts continue to show strength. This has allowed the society to maintain a healthy reserve, providing us with stability and opportunities for future growth.

Lastly, I would like to thank the PCRS Board of Directors for their dedication and leadership. Our society is in a strong position to continue flourishing, with the positive changes already in motion and new leaders such as our President, Dr. Alex Quass stepping forward to guide us. I look forward to seeing PCRS continue to thrive in the years to come.

Warmest regards,  
Tamara Tobias, ARNP  
Immediate Past President, Pacific Coast Reproductive Society



# CURRENT PRESIDENT'S MESSAGE

Dear PCRS Supporters & Friends,

Our society is thriving- the 2024 PCRS Annual Meeting was the most attended annual meeting in the history of our association. Member engagement is also at an all-time high, and it is a pleasure to see the work of the various task forces- the Abstract/Awards, Scholarship, Grant, Membership, Program, Social Media/Communications Committees.

Our upcoming 2025 meeting carries the theme "Pacific Waves – Exploring Scientific Frontiers in an Evolving Society". Led by Nicole Doyle, the PCRS Planning Committee is preparing an amazing program for 2025 featuring lectures, abstracts, debates, and networking opportunities. Brace yourself for many potential meeting highlights, including research and art presentations by the internationally renowned Professor Emerita of Family Research Susan Golombok on the topic of "Modern Families"; and- by popular demand- a revival of the "Richard versus Richard" PGT-A debate featuring one of the "Godfathers" of PCRS, Richard Paulson, and Richard Scott, a pioneer in the area of genetic testing in ART.

The 2024 PCRS Annual Meeting carried the title "Innovation and Integration: The Future of Reproductive Medicine", and our amazing Immediate Past President Tamara Tobias chose a "Frozen" theme- inspired by the 40th anniversary of the first birth from a frozen embryo, Zoe Leyland, born March 28, 1984, in Australia. Led by Program Chair Debbie Venier, the PCRS Planning Committee put together an excellent program featuring lectures, abstracts, debates, and networking opportunities. The oral abstract presentations and posters were outstanding and well-received. Feedback from attendees indicates a desire for more original research oral presentations, which the 2025 program committee integrated in their planning of the next meeting. This year we had 86 total sponsors and exhibitors who showcased their latest innovations and contributions to our field. A special thank you to the following sponsors: Ferring Pharmaceuticals (Diamond); EMD Serono (Ruby); Organon (Sapphire); CooperSurgical, IVF Store, TMRW, PHCBI (Topaz); and Exem Foam, FujiFilm, Ovation Fertility, Samsung, Vitrolife, GranataBio, CCRM Fertility, Natara, Reproductive Medicine Associates (Supporting).

Thanks to Ferring Pharmaceuticals' generous research grant, it has now become a tradition for PCRS to award grant funding to two recipients and support their great research. We consistently receive at least 10 high quality grant submissions every year - it is remarkable to see the output and contributions from our PCRS members, especially from those in training.

Our field is going through exciting times of scientific advances, but also worrisome times with threats to the state-of-the-art practice of reproductive medicine. To learn and discuss the latest updates on these diverse aspects, you can look forward to a 2025 meeting of great interest to all members of the multidisciplinary care team.

When I am overwhelmed by the latest advances, or anxious about the future of our field, PCRS gives me hope. I very much look forward to seeing you in Indian Wells in March 2025.

Kind regards,  
Alex Quaas, MD PhD  
President, Pacific Coast Reproductive Society



# ABOUT PCRS AND ORGANIZATIONAL MISSION AND VISION

Pacific Coast Reproductive Society is a multidisciplinary medical specialty society providing Continuing Medical Education (CME) to physicians and allied healthcare professionals. PCRS offers the highest quality, innovative CME, designed and presented by thought leaders in reproductive medicine.

PCRS provides an outstanding forum for the exchange of information, and the advancement of the ideologies of reproductive medicine in a relaxed and collegial setting building relationships that foster the integration of current knowledge to ensure quality medical care for patients.

## OUR VISION

- PCRS is a global, interactive organization championing the field of reproductive medicine.



## OUR VALUES

- Support of physicians, their teams, and allied professional
- Innovation
- Inclusiveness
- Collegiality

## **SUPPORTIVE**

- Member and Sponsor supported scholarship program for REI Fellows and other trainees to attend Annual Meeting
- Leadership development through Junior and Senior level committee service and Board Directorship
- Concierge service for attendees, exhibitors, and sponsors

## **INNOVATIVE**

- Website enables convenient, time-effective online interactions with members, attendees, faculty, authors, volunteers exhibitors and sponsors
- Program Planning committee members rotate each year to provide fresh and timely educational activities and content

## **INCLUSIVE**

- Complimentary membership to all REI trainees; discounted membership to allied healthcare teammates
- PCRS Board and Committees reflect an inter-professional workforce, including physicians, biologists, nurses, counselors, and practice management
- Members include medical students, residents, fellows, both practicing and retired physician, and allied health professional

## COLLEGIATE

- PCRS Demands an even playing field among REI professionals
- Relationships with SGI, ASRM, CFS, and Fertility & Sterility provide gateways of advancement and partnership for PCRS members
- PCRS Annual Meeting Evaluations contribute to efficacy of REI field of medicine

## PROFESSIONAL

- PCRS CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide CME to physicians
- Nurse and genetic counselors may apply for CEUs from their appropriate accrediting bodies with their PCRS certificate of attendance
- Abstracts published by PCRS are peer-reviewed and selected by an interprofessional committee of REI experts

## INTIMATE


- PCRS sessions teach to the team of individuals in reproductive medicine
- Informal dress code promotes an environment of collegiality and solidarity
- Annual Meeting blends education with networking to allow ample learning and opportunity to build and foster relationships

# ABSTRACT SUBMISSION

PCRS continues to be a global, interactive organization promoting leadership and innovation in reproductive medicine within a collegial environment. The annual CME program is based on the integration of clinical practice, scientific research, and education in the field of reproductive medicine.

More than one hundred and twenty abstracts were selected for oral or poster presentation at the 2024 annual meeting and were also published in a special digital edition of *Fertility & Sterility*.

**Abstract Submissions**



# SCHOLARSHIP PROGRAM

To encourage the participation of medical professionals in-training, particularly fellows specializing in reproductive medicine, PCRS established a Scholarship Program made possible by funding from Society members and commercial sponsors.

## Scholarship Types & Eligibility Requirements

### **MD Scholarship**

Open to all fellows in US REI programs, residents, and medical students who have not previously attended PCRS on a scholarship.

### **Merit Scholarship**

Open to any PCRS scholarship winners from previous years who will be the presenting author of an abstract submitted for presentation at the meeting.

### **REI Lab Scholarship**

Open to all non-management IVF laboratory professionals who are the presenting author of an abstract submitted for presentation at the meeting.


### **Nurses and Genetic Counselors**

Open to all nurses and genetic counselors who have not attended a PCRS meeting in the past or are the presenting author of an abstract submitted for presentation at the meeting.




# SCHOLARSHIPS AWARDED

Scholarships Awarded



# SCHOLARSHIP PROGRAM


Scholarship Program



# SPONSORED RESEARCH GRANTS


PCRS supports innovative research projects in reproductive medicine for current Reproductive Endocrinology, Infertility Fellows and New Investigators who have completed their professional training in the last three years. The generous donation from Ferring Pharmaceuticals Inc, enables PCRS to award \$20,000 in annual research grants. Funds are available for project expenses, technical assistance, patient express, research supplies, and durable laboratory equipment.

**PCRS Research Grants are sponsored by Ferring Pharmaceuticals, Inc.**




# COMMERCIAL SPONSORS

Commercial Sponsors




# REVENUE FROM EXHIBIT FEES

Exhibit Fees




# REVENUE FROM ATTENDEE FEES

Attendee Fees




# ENDOWMENT FUND BALANCE

Endowment Fund



# DUES REVENUE

Dues





# KEY FINANCIAL STATISTICS

|                                  | <u>2016 -2017</u> | <u>2017 - 2018</u> | <u>2018 - 2019</u> | <u>2019-2020</u> |
|----------------------------------|-------------------|--------------------|--------------------|------------------|
| <b>Reserves</b>                  | 1,034,536.03      | 1,004,614.00       | 859,522.29         | 901,381.78       |
| <b>Operating Expenses</b>        | 204,576.00        | 295,401.00         | 285,593.89         | 320,837.90       |
| <b>Ratio</b>                     | 5.06              | 3.40               | 3.01               | 2.81             |
| <b>Income</b>                    | 1,021,242.18      | 956,782.00         | 963,087.51         | 42,462.04        |
| <b>Expense</b>                   | 866,184.00        | 1,006,107.00       | 693,573.62         | 1,850,454.00     |
| <b>Commercial Support</b>        | 432,350.00        | 345,690.00         | 300,550.00         | 0.00             |
| <b>Program Revenue</b>           | 511,237.00        | 535,312.00         | 206,655.00         | 2,015.00         |
| <b>Dues</b>                      | 47,155.00         | 41,855.00          | 54,000.00          | 28,325.00        |
| <b>Member Meeting Attendance</b> | 271               | 271                | 312                | 0                |
| <b>Active Members</b>            | 224               | 187                | 215                | 318              |
| <b>Member Retention %</b>        | 69.7%             | 78.1%              | 71.2%              | 92.8%            |

|                                  | <u>2020-2021</u> | <u>2021-2022</u> | <u>2022-2023</u> | <u>2023-2024</u> |
|----------------------------------|------------------|------------------|------------------|------------------|
| <b>Reserves</b>                  | 1,308,803.43     | 957,527          | 1047000.50       | 1,157,119.34     |
| <b>Operating Expenses</b>        | 198,143.53       | 260,151.67       | 246,618.43       | 262,228.81       |
| <b>Ratio</b>                     | 6.61             | 3.68             | 4.25             | 4.41             |
| <b>Income</b>                    | 213,846.53       | 914,316.82       | 878151.15        | 1,097,123.90     |
| <b>Expense</b>                   | 302,514.54       | 727,543.53       | 792591.54        | 819,830.53       |
| <b>Commercial Support</b>        | 103,595.00       | 232,700.00       | 207,650.00       | 290,800.00       |
| <b>Program Revenue</b>           | 36,945.00        | 238,764.00       | 256,050.00       | 304,100.00       |
| <b>Dues</b>                      | 14,800.00        | 57,135.00        | 55,490.00        | 65,130.00        |
| <b>Member Meeting Attendance</b> | 238              | 145              | 215              | 280              |
| <b>Active Members</b>            | 235              | 364              | 334              | 402              |
| <b>Member Retention %</b>        | 78.3%            | 92%              | 91%              | 94%              |

# BALANCE SHEET

|  | Jun 30, 24          | Jun 30, 23          | \$ Change         | % Change       |
|--|---------------------|---------------------|-------------------|----------------|
| <b>ASSETS</b>                                  |                     |                     |                   |                |
| <b>Current Assets</b>                          |                     |                     |                   |                |
| Checking/Savings                               |                     |                     |                   |                |
| 1010 · Business Premium Market Rate            | 177,229.90          | 86,986.02           | 90,243.88         | 103.75%        |
| 1030 · Wells PCRS Checking 5963                | 501,241.94          | 344,441.48          | 156,800.46        | 45.52%         |
| <b>Total Checking/Savings</b>                  | <b>678,471.84</b>   | <b>431,427.50</b>   | <b>247,044.34</b> | <b>57.26%</b>  |
| Other Current Assets                           |                     |                     |                   |                |
| 1300 · Prepaid Fees                            | 27,371.50           | 17,622.50           | 9,749.00          | 55.32%         |
| <b>Total Other Current Assets</b>              | <b>27,371.50</b>    | <b>17,622.50</b>    | <b>9,749.00</b>   | <b>55.32%</b>  |
| <b>Total Current Assets</b>                    | <b>705,843.34</b>   | <b>449,050.00</b>   | <b>256,793.34</b> | <b>57.19%</b>  |
| <b>Fixed Assets</b>                            |                     |                     |                   |                |
| 1500 · Asset /Web-Site Development             | 30,000.00           | 30,000.00           | 0.00              | 0.0%           |
| 1550 · Equip & Fixed Asset Accum. Depr         | -30,000.00          | -30,000.00          | 0.00              | 0.0%           |
| <b>Total Fixed Assets</b>                      | <b>0.00</b>         | <b>0.00</b>         | <b>0.00</b>       | <b>0.0%</b>    |
| <b>Other Assets</b>                            |                     |                     |                   |                |
| 1600 · Investments                             |                     |                     |                   |                |
| Holdings - Scholarship Endowmen                |                     |                     |                   |                |
| Schola End Unrealized Gain/Loss                | 63,699.56           | 49,754.76           | 13,944.80         | 28.03%         |
| Scholar Endow - Vanguard                       | 124,843.00          | 124,843.00          | 0.00              | 0.0%           |
| Scholar Endowment Dividends                    | 20,158.99           | 14,242.41           | 5,916.58          | 41.54%         |
| <b>Total Holdings - Scholarship Endowmen</b>   | <b>208,701.55</b>   | <b>188,840.17</b>   | <b>19,861.38</b>  | <b>10.52%</b>  |
| 1610 · Holdings - Investment Fund              |                     |                     |                   |                |
| 1615 · Inv Fund Unrealized Gain/Loss           | 263,656.89          | 200,286.54          | 63,370.35         | 31.64%         |
| 1620 · Investment Fund Dividends               | 84,760.90           | 57,873.79           | 26,887.11         | 46.46%         |
| 1630 · Investments Fund                        | 600,000.00          | 600,000.00          | 0.00              | 0.0%           |
| <b>Total 1610 · Holdings - Investment Fund</b> | <b>948,417.79</b>   | <b>858,160.33</b>   | <b>90,257.46</b>  | <b>10.52%</b>  |
| <b>Total 1600 · Investments</b>                | <b>1,157,119.34</b> | <b>1,047,000.50</b> | <b>110,118.84</b> | <b>10.52%</b>  |
| <b>Total Other Assets</b>                      | <b>1,157,119.34</b> | <b>1,047,000.50</b> | <b>110,118.84</b> | <b>10.52%</b>  |
| <b>TOTAL ASSETS</b>                            | <b>1,862,962.68</b> | <b>1,496,050.50</b> | <b>366,912.18</b> | <b>24.53%</b>  |
| <b>LIABILITIES &amp; EQUITY</b>                |                     |                     |                   |                |
| <b>Liabilities</b>                             |                     |                     |                   |                |
| <b>Current Liabilities</b>                     |                     |                     |                   |                |
| Accounts Payable                               |                     |                     |                   |                |
| 2000 · Accounts Payable                        | 0.00                | 15,410.03           | -15,410.03        | -100.0%        |
| <b>Total Accounts Payable</b>                  | <b>0.00</b>         | <b>15,410.03</b>    | <b>-15,410.03</b> | <b>-100.0%</b> |
| Other Current Liabilities                      |                     |                     |                   |                |
| 2500 · Deferred Dues                           | 0.00                | 15,740.00           | -15,740.00        | -100.0%        |
| 2600 · Deferred Annual Meeting                 | 10,650.00           | 0.00                | 10,650.00         | 100.0%         |
| <b>Total Other Current Liabilities</b>         | <b>10,650.00</b>    | <b>15,740.00</b>    | <b>-5,090.00</b>  | <b>-32.34%</b> |
| <b>Total Current Liabilities</b>               | <b>10,650.00</b>    | <b>31,150.03</b>    | <b>-20,500.03</b> | <b>-65.81%</b> |
| <b>Total Liabilities</b>                       | <b>10,650.00</b>    | <b>31,150.03</b>    | <b>-20,500.03</b> | <b>-65.81%</b> |
| <b>Equity</b>                                  |                     |                     |                   |                |
| 3001 · Fund Balance - Unallocated              | 107,781.13          | 67,390.94           | 40,390.19         | 59.93%         |
| 3050 · Investment Fund                         | 948,417.79          | 830,164.15          | 118,253.64        | 14.25%         |
| 3060 · Operating Fund                          | 200,000.00          | 200,000.00          | 0.00              | 0.0%           |
| 3070 · Schl. Endowment Fund                    | 208,701.55          | 182,679.54          | 26,022.01         | 14.25%         |
| Net Income                                     | 387,412.21          | 184,665.84          | 202,746.37        | 109.79%        |
| <b>Total Equity</b>                            | <b>1,852,312.68</b> | <b>1,464,900.47</b> | <b>387,412.21</b> | <b>26.45%</b>  |
| <b>TOTAL LIABILITIES &amp; EQUITY</b>          | <b>1,862,962.68</b> | <b>1,496,050.50</b> | <b>366,912.18</b> | <b>24.53%</b>  |



PACIFIC COAST  
REPRODUCTIVE  
SOCIETY